J
JenaValve Technology
A medical device company focused on the design and development of innovative transcatheter heart valve solutions
About JenaValve Technology
JenaValve is a medical technology startup that focuses on developing innovative solutions for patients with severe aortic regurgitation, a condition where the heart's aortic valve doesn't close tightly, causing blood to leak back into the heart. The company's flagship product is the Trilogy System, a Transcatheter Aortic Valve Replacement (TAVR) solution. TAVR is a minimally invasive procedure that replaces the aortic valve without the need for open-heart surgery.
JenaValve's primary market is the aging population, as the prevalence of valvular heart disease, including aortic regurgitation, increases with age. The company's business model revolves around the development, production, and sale of the Trilogy System to healthcare providers. They also provide training and support for the use of their system.
The company generates revenue through the sale of the Trilogy System to hospitals and clinics. They also partner with other organizations, like the American Society of Echocardiography (ASE), to advance the detection and diagnosis of aortic regurgitation, which could potentially increase the demand for their product.
JenaValve's recent trials, such as the ALIGN-AR trial, have shown promising results, meeting safety and efficacy endpoints. This suggests that the Trilogy System could become a leading solution for treating severe aortic regurgitation in the future.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Irvine, United States
- Employees
- 215
- Open positions
- 44
- Dealroom signal
- 55.2/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Risk Management, Cardiology and cardiovascular, Spinout, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2024 | $0 | — | Edwards Lifesciences | ↗ |
| SERIES COther financing | Aug 2022 | $100M | $400M | Gimv · Qatar Investment Authority · Pictet · Cormorant Asset Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for JenaValve Technology is 9.4K monthly website visits, down 1.1% over the last three months. JenaValve Technology's team grew 45.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Fraunhofer Venture
Heartcore Capital
NeoMed
Gimv
Atlas Venture
VI Partners
Andera Partners
Series B and later14 investors entered at this stage
Legend Capital
Omega Funds
Valiance Asset Management- VIValiance Life Science Investments
RMM
Bain Capital Life Sciences
Valiance Partners
Armentum Partners
Qatar Investment Authority
Pictet
Cormorant Asset Management
Peijia Medical
Innovatus Capital Partners- VIVenture Incubator
Other known investors3 additional known investors
Edwards Lifesciences
Fraunhofer Society - Fraunhofer Gesellschaft
Jenaversum
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about JenaValve Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JenaValve Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.